AngioDynamics CEO Jim Clemmer announced his retirement, causing uncertainty and a 13.1% drop in stock. Despite this, Q3 results were positive with revenue of $79.4 million, higher than estimates. Clemmer will continue leading until a successor is found. The board is searching for a new CEO with help from an executive search firm.

Investors are wary of the uncertainty caused by Clemmer’s departure. However, AngioDynamics has seen improvements, increasing net sales and EBITDA guidance. They also received FDA clearance for a modified AlphaVac F1885 System. Analysts suggest the sell-off is overdone, but other stocks may offer better opportunities.

The Motley Fool Stock Advisor team identified 10 top stocks for investors to buy, none of which include AngioDynamics. Previous recommendations like Netflix and Nvidia have seen significant returns. Stock Advisor boasts a total average return of 973%, outperforming the S&P 500. Don’t miss out on the latest top 10 list for potential high returns.

Read more at Yahoo Finance: Why AngioDynamics Stock Is Sinking Today